To develop a novel nomogram that combines clinical, biopsy and multiparametric magnetic resonance imaging (mpMRI) findings and to compare its predictive accuracy to, respectively: 1) Prostate Cancer Research International: Active Surveillance (PRIAS) criteria, 2) Johns Hopkins (JH) criteria, 3) EAU low risk classification and 4) EAU low risk or low volume ISUP GG2 classification. Overall, we selected 1 837 patients with ISUP GG 1 or ISUP GG2 prostate cancer that were treated with radical prostatectomy (RP) between 2012 and 2018. The outcome of interest was the presence of unfavourable disease (csPCa) at RP, defined as: ISUP GG≥3 and/or pT≥3a and/or pN1. First, logistic regression models including PRIAS, JH, EAU low risk and EAU low risk or low volume ISUP GG2 binary classifications (not eligible vs. eligible) were used. Second, a multivariable logistic regression model including age, PSA-D, ISUP GG and the percentage of positive cores (Model 1) was fitted. Third, PI-RADS score (Model 2), extracapsular score (ECE) (Model 3) and PI-RADS + ECE score (Model 4) were added to Model 1. Only variables associated with higher csPCa rates in Model 4 were retained in the final simplified Model 5. The area under the ROC-curve (AUC), calibration plots and decision-curve analyses were used. Of 1 837 patients, 775 (42.2%) presented csPCa at RP. Overall, 837 (47.5%), 986 (53.7%), 348 (18.9%) and 209 (11.4%) patients were eligible to AS according to, respectively, low risk classification, low risk or low volume ISUP GG2 classification, PRIAS criteria and JH criteria. The proportion of csPCa among low risk, low risk or low volume ISUP GG2, PRIAS and JH candidates was, respectively 28.5%, 29.3%, 25.6% and 17.2%. Model 4 and Model 5 (in which only PSA-D, ISUP GG, PI-RADS and ECE score were retained) had greater AUC (0.84), compared to the four proposed AS criteria (all p<0.001). The adoption of a 25% nomogram threshold increased the proportion of AS eligible patients from 18.9% (PRIAS) and 11.4% (JH) to 44.4%. Moreover, the same 25% nomogram threshold resulted in significantly lower estimated risks of csPCa (11.3%), compared to PRIAS (∆:-14.3%), JH (∆:-5.9%), low risk (∆:-17.2%) and low risk or low volume ISUP GG2 (∆:-18.0%) classifications. A novel nomogram that combines clinical, biopsy and mpMRI findings is able to increase of approximately 25% and 35% the absolute frequency of patients suitable for AS, compared to, respectively, PRIAS or JH criteria. Moreover, this nomogram significantly reduces the estimated frequency of csPCa that would be recommended for AS compared to, respectively, PRIAS, JH, EAU low risk and EAU low volume ISUP GG2 classifications.

A novel nomogram to identify candidates for active surveillance among patients with ISUP Grade Group 1 or ISUP Grade Group 2 prostate cancer, according to multiparametric magnetic resonance imaging findings / S. Luzzago, O. de Cobelli, G. Cozzi, G. Peveri, V. Bagnardi, M. Catellani, E. Di Trapani, F.A. Mistretta, P. Pricolo, A. Conti, S. Alessi, G. Marvaso, M. Ferro, D. Matei, G. Renne, B. Jereczek-Fossa, G. Petralia, G. Musi. - In: BJU INTERNATIONAL. - ISSN 1464-4096. - (2020). [Epub ahead of print] [10.1111/bju.15048]

A novel nomogram to identify candidates for active surveillance among patients with ISUP Grade Group 1 or ISUP Grade Group 2 prostate cancer, according to multiparametric magnetic resonance imaging findings

S. Luzzago
Primo
;
O. de Cobelli
Secondo
;
G. Peveri;M. Catellani;F.A. Mistretta;A. Conti;G. Marvaso;B. Jereczek-Fossa;G. Petralia
Penultimo
;
G. Musi
2020

Abstract

To develop a novel nomogram that combines clinical, biopsy and multiparametric magnetic resonance imaging (mpMRI) findings and to compare its predictive accuracy to, respectively: 1) Prostate Cancer Research International: Active Surveillance (PRIAS) criteria, 2) Johns Hopkins (JH) criteria, 3) EAU low risk classification and 4) EAU low risk or low volume ISUP GG2 classification. Overall, we selected 1 837 patients with ISUP GG 1 or ISUP GG2 prostate cancer that were treated with radical prostatectomy (RP) between 2012 and 2018. The outcome of interest was the presence of unfavourable disease (csPCa) at RP, defined as: ISUP GG≥3 and/or pT≥3a and/or pN1. First, logistic regression models including PRIAS, JH, EAU low risk and EAU low risk or low volume ISUP GG2 binary classifications (not eligible vs. eligible) were used. Second, a multivariable logistic regression model including age, PSA-D, ISUP GG and the percentage of positive cores (Model 1) was fitted. Third, PI-RADS score (Model 2), extracapsular score (ECE) (Model 3) and PI-RADS + ECE score (Model 4) were added to Model 1. Only variables associated with higher csPCa rates in Model 4 were retained in the final simplified Model 5. The area under the ROC-curve (AUC), calibration plots and decision-curve analyses were used. Of 1 837 patients, 775 (42.2%) presented csPCa at RP. Overall, 837 (47.5%), 986 (53.7%), 348 (18.9%) and 209 (11.4%) patients were eligible to AS according to, respectively, low risk classification, low risk or low volume ISUP GG2 classification, PRIAS criteria and JH criteria. The proportion of csPCa among low risk, low risk or low volume ISUP GG2, PRIAS and JH candidates was, respectively 28.5%, 29.3%, 25.6% and 17.2%. Model 4 and Model 5 (in which only PSA-D, ISUP GG, PI-RADS and ECE score were retained) had greater AUC (0.84), compared to the four proposed AS criteria (all p<0.001). The adoption of a 25% nomogram threshold increased the proportion of AS eligible patients from 18.9% (PRIAS) and 11.4% (JH) to 44.4%. Moreover, the same 25% nomogram threshold resulted in significantly lower estimated risks of csPCa (11.3%), compared to PRIAS (∆:-14.3%), JH (∆:-5.9%), low risk (∆:-17.2%) and low risk or low volume ISUP GG2 (∆:-18.0%) classifications. A novel nomogram that combines clinical, biopsy and mpMRI findings is able to increase of approximately 25% and 35% the absolute frequency of patients suitable for AS, compared to, respectively, PRIAS or JH criteria. Moreover, this nomogram significantly reduces the estimated frequency of csPCa that would be recommended for AS compared to, respectively, PRIAS, JH, EAU low risk and EAU low volume ISUP GG2 classifications.
Active surveillance; International Society of Urological Pathology Grade Groups; Multiparametric-magnetic resonance imaging; Nomogram; Prostate Cancer
Settore MED/24 - Urologia
Settore MED/36 - Diagnostica per Immagini e Radioterapia
9-mar-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
Luzzago_et_al-2020-BJU_International.pdf

embargo fino al 09/03/2021

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 2.25 MB
Formato Adobe PDF
2.25 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/720012
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 12
social impact